Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

There are three types of Neurofibromatosis; Neurofibromatosis type 1, Neurofibromatosis type 2, and Schwannomatosis. Neurofibromatosis type (NF) 1 is a common monogenic disorder of neurocutaneous tissue growth that arises secondary to mutations in the tumor suppressor gene NF1. It features an autosomal dominant pattern of inheritance. Individuals with NF1 typically have an increased predisposition to a variety of benign and malignant tumors and develop neurofibromas, and axillary and inguinal freckling. Neurofibromatosis 2 (NF2) is less common than NF1. Common signs and symptoms of NF 2 include benign, slow-growing tumors affecting the cranial, spinal, and peripheral nerves, as well as the meninges. KOSELUGO- selumetinib is the only drug available for the treatment of Neurofibromatosis Type-1. Moreover, some drugs such as bevacizumab are also used as off-label for the treatment of Neurofibromatosis

The global neurofibromatosis treatment drugs market is estimated to be valued at US$ 8,801.0  million in 2020 and is expected to exhibit a CAGR of 13.40% during the forecast period (2020-2027).

Figure 1. Global Neurofibromatosis Treatment Drugs Market Value (US$ Mn)

Neurofibromatosis Treatment Drugs  | Coherent Market Insights

Global Neurofibromatosis Treatment Drugs Market: Drivers

Increasing focus of major players on research and development of novel therapies for treating neurofibromatosis. Moreover, clinical studies are well supported by regulatory authorities which is expected to drive the growth of the global neurofibromatosis treatment drugs market. For instance, in October 2019, SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, initiated the Phase 2b ReNeu clinical trial to evaluate the mirdametinib (formerly PD-0325901), an oral, small molecule designed to inhibit MEK1 and MEK2, in children and adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (NF1-PN). In July 2019, the European Commission granted Orphan Drug Designation for SpringWorks Therapeutics’ mirdametinib (formerly PD-0325901), an oral, small molecule inhibitor of MEK1 and MEK2, for the treatment of neurofibromatosis type 1 (NF1).

request-sample

Neurofibromatosis Treatment Drugs Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 8,801.0 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 13.4% 2027 Value Projection: US$ 8,801.0 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of the Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Disease Type: Neurofibromatosis 1 (NF1), Neurofibromatosis 2 (NF2), Schwannomatosis.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

AstraZeneca Plc.

Growth Drivers:
  • Strong product pipeline, approval of new pediatric drugs, and outsourcing for drug development activities
  • Commercial tie-ups and acquisitions by key players
  • Innovation in clinical research
Restraints & Challenges:
  • Difficulty in conducting clinical trials for pediatric population

Global Neurofibromatosis Treatment Drugs Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID 19) pandemic and lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. Private healthcare is one such sector, which has been majorly impacted by the COVID-19 pandemic.

The lockdown in various countries due to the pandemic has placed an economic burden on the private healthcare sector.

Moreover, the coronavirus pandemic has hampered the development, production, and supply of healthcare products (medical devices and medicinal products) and affected growth of healthcare businesses of various companies across the globe.

The lockdowns have led to closure of industrial establishments, except manufacturing of essential commodities, and disrupted supply chains.

The COVID-19 pandemic has affected the economy in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) by its financial impact on firms and financial markets

As a result, the impact of coronavirus (COVID-19) pandemic is also expected to limit growth of the global neurofibromatosis treatment drugs market during the forecast period.

Figure 2. Global Neurofibromatosis Treatment Drugs Market Value (US$ Mn), by Region, 2020

Neurofibromatosis Treatment Drugs  | Coherent Market Insights

North America neurofibromatosis treatment drugs market is expected to show significant growth during the forecast period owing to presence of key players and research institutes who are involved in clinical trial programmes. For instance, on November 28, 2017, the University of Alabama at Birmingham initiated phase 2 clinical study on Binimetinib in children and adults with nf1 plexiform neurofibromas. On February 18, 2020, the University of Alabama at Birmingham initiated phase 2 clinical trial of crizotinib for children and adults with neurofibromatosis type 2 and progressive vestibular.

Key Players

Major Player operating in the global neurofibromatosis treatment drugs market is AstraZeneca Plc.

Neurofibromatosis is a genetic disorder of the nervous system. It mainly affects growth of nerve cells. It is characterized by the growth of tumors on nerves. Neurofibromatosis is considered as a hereditary disease which mainly occurs in children or it can happen due to mutation (change) of genes. Usually the Neurofibromatosis tumors are benign, but sometimes they can become cancerous. There are three types of neurofibromatosis: Type 1 (NF1), Type 2 (NF2), and Schwannomatosis. All three types show varied symptoms.

Market Dynamics

The increasing focus of pharma and biotech companies on the research and development of novel treatment drugs for neurofibromatosis is expected to drive the neurofibromatosis treatment drugs market growth during the forecast period. For instance, on July 8, 2020, Nobelpharma initiated phase 3 clinical trial study to evaluate the safety and efficacy of long-term treatment with NPC-12G gel for patients with neurofibromatosis type I. The study is estimated to complete in April 30, 2022.

Key features of the study:

  • This report provides in-depth analysis of the global neurofibromatosis treatment drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global neurofibromatosis treatment drugs market based on the following parameters – company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key company covered as a part of this study includes AstraZeneca
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global neurofibromatosis treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neurofibromatosis treatment drugs market.

Detailed Segmentation:

  • Global Neurofibromatosis treatment drugs market, By Disease Type:
    • Neurofibromatosis 1 (NF1)
    • Neurofibromatosis 2 (NF2)
    • Schwannomatosis
  • Global Neurofibromatosis treatment drugs market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Neurofibromatosis treatment drugs market, By Region:
    • North America
      • By Disease Type:
        • Neurofibromatosis 1 (NF1)
        • Neurofibromatosis 2 (NF2)
        • Schwannomatosis
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Disease Type:
        • Neurofibromatosis 1 (NF1)
        • Neurofibromatosis 2 (NF2)
        • Schwannomatosis
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Disease Type:
        • Neurofibromatosis 1 (NF1)
        • Neurofibromatosis 2 (NF2)
        • Schwannomatosis
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Disease Type:
        • Neurofibromatosis 1 (NF1)
        • Neurofibromatosis 2 (NF2)
        • Schwannomatosis
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Disease Type:
        • Neurofibromatosis 1 (NF1)
        • Neurofibromatosis 2 (NF2)
        • Schwannomatosis
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Disease Type:
        • Neurofibromatosis 1 (NF1)
        • Neurofibromatosis 2 (NF2)
        • Schwannomatosis
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profile
    • AstraZeneca *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Disease Type
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
      • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Impact Analysis
    • Market Opportunities
    • Collaborations and Acquisition
    • Regulatory Scenario
  4. Global Neurofibromatosis Treatment Drugs Market, Impact of COVID-19 Pandemic
    • During COVID-19 Impact
    • Post COVID-19 Impact
    • Government Initiatives
    • Overall Impact On Healthcare Industry
  5. Global Neurofibromatosis Treatment Drugs Market, By Disease Type, 2016-2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
        • Neurofibromatosis 1 (NF1)
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Neurofibromatosis 2 (NF2)
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
        • Schwannomatosis
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  6. Global Neurofibromatosis Treatment Drugs Market, By Distribution Channel, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017– 2027
      • Segment Trends
        • Hospital Pharmacies
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
        • Retail Pharmacies
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
        • Online Pharmacies
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
  7. Global Neurofibromatosis Treatment Drugs Market, By Region, 2016–2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, By Country, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Countries, 2017–2027
    • North America
      • Introduction
      • Market Size and Forecast, By Disease Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, By Disease Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, By Disease Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • Germany
        • U.K.
        • France       
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, By Disease Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, By Disease Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, By Disease Type, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016–2027 (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  8. Competitive Landscape
    • Company Profiles
      • AstraZeneca Plc.*
        • Company Overview
        • Disease Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies

*Browse 22 market data tables and 24 figures on "Global Neurofibromatosis Treatment Drugs Market– Global forecast to 2027”.

Frequently Asked Questions

The global neurofibromatosis treatment drugs market is estimated to be valued at US$ 8,801.0 million in 2020 and is expected to exhibit a CAGR of 13.4% between 2020 and 2027.
Strong product pipeline, approval of new drugs and commercial tie-ups and acquisitions by key players, and innovation in clinical research are driving growth of the global neurofibromatosis treatment drugs market.
NF-1 is the leading disease type segment in the global neurofibromatosis treatment drugs market and it is estimated to hold major market share in 2020 owing to the increasing number of drug trials and approvals.
North America is the leading region in the global neurofibromatosis treatment drugs market and is estimated to account for the highest revenue share in 2020.
Difficulty in conducting pediatric clinical trial due lack of pediatric participants is a key factor hampering growth of the market.
Major player operating in the global neurofibromatosis treatment drugs market is AstraZeneca.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner